SLC5A2 and type 2 diabetes mellitus: The novel antidiabetic agents, SGLT2 inhibitors, have been gradually reconsidered as an important class of medications for heart failure, being recommended for their beneficial impact in patients with type 2 diabetes patients and multiple cardiovascular risk factors or heart failure with reduced ejection fraction [11].